ZIDITUF-TZ 281.25 Injection

Advanced Antibiotic Therapy for Effective Infection Management

ZIDITUF-TZ 281.25 Injection combines Ceftazidime 250 mg and Tazobactam 31.25 mg to provide broad-spectrum antibacterial coverage against a wide range of bacterial infections. This combination is designed to enhance the effectiveness of Ceftazidime by protecting it from bacterial resistance mechanisms, making it a reliable choice for the treatment of susceptible infections.

Composition

Each vial contains:

• Ceftazidime 250 mg
• Tazobactam 31.25 mg

Mechanism of Action (MOA)

Ceftazidime

Ceftazidime is a third-generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis. It prevents bacteria from forming a protective cell wall, leading to bacterial destruction and elimination of infection.

Tazobactam

Tazobactam is a beta-lactamase inhibitor that helps protect Ceftazidime from degradation by beta-lactamase enzymes produced by certain resistant bacteria. This improves the antibiotic’s effectiveness and extends its antibacterial spectrum.

Key Benefits

• Broad-spectrum antibacterial activity
• Enhanced efficacy against beta-lactamase-producing bacteria
• Effective against susceptible Gram-negative and Gram-positive organisms
• Helps manage mild to severe bacterial infections
• Supports faster infection control and recovery
• Trusted combination for hospital and clinical use

Indications

ZIDITUF-TZ 281.25 Injection may be prescribed for the treatment of:

• Respiratory tract infections
• Pneumonia
• Urinary tract infections (UTIs)
• Skin and soft tissue infections
• Intra-abdominal infections
• Bone and joint infections
• Ear, nose and throat infections
• Gynecological infections
• Septicemia
• Post-operative infections
• Infections caused by susceptible Pseudomonas species and other bacteria

Why Choose ZIDITUF-TZ 281.25?

The combination of Ceftazidime and Tazobactam offers enhanced antibacterial protection by addressing bacterial resistance mechanisms. This helps healthcare professionals achieve better clinical outcomes in the management of bacterial infections.

Dosage and Administration

The dosage and duration of treatment should be determined by a qualified healthcare professional based on the patient’s condition, age, severity of infection, and clinical response.

Safety Information

• To be administered only under medical supervision.
• Not effective against viral infections.
• Inform your healthcare provider about any history of allergy to cephalosporins, penicillins, or other antibiotics.
• Store as directed on the product label.
• Keep out of reach of children.